Press Releases - Archive

Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System
November 28, 2018

Blaze Bioscience Announces Presentation of Tumor Paint BLZ-100 Clinical Data at Pediatric Neuro-Oncology Basic and Translational Research Conference
June 15, 2017

Blaze Bioscience Announces Presentation of Tumor Paint BLZ-100 Clinical Data at the American Society of Breast Surgeons (ASBrS) Annual Meeting
April 27, 2017

Blaze Bioscience Announces Tumor Paint BLZ-100 Publication in International Journal of Toxicology
March 28, 2017

Blaze Bioscience Announces Trial in Progress Presentation at ASCO 2016 Annual Meeting
May 31, 2016

Blaze Bioscience Announces Tumor Paint BLZ-100 Publication in JAMA Otolaryngology Head & Neck Surgery
February 25, 2016

Blaze Bioscience to Present Tumor Paint BLZ-100 at SPIE Photonics West Conference
February 11, 2016

Blaze Bioscience to Present Tumor Paint Clinical Data at 20th Annual Society for Neuro-Oncology (SNO) Meeting
November 9, 2015

Blaze Bioscience Announces Presentation at GAC-SC 2015 Conference
October 27, 2015

Blaze Bioscience Announces Publication of Tumor Paint BLZ-100 Data in Cancer Research
October 15, 2015

Blaze Bioscience Commences Clinical Trial of BLZ-100 in Patients with Sarcoma Undergoing Surgery
September 22, 2015

Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Patients with Solid Tumor Cancers
July 14, 2015

Blaze Bioscience's BLZ-100 Receives Orphan Drug Designation from FDA for Brain Cancer
July 7, 2015

Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer
June 4, 2015

Blaze Bioscience An noun ces Poster Presentation at ASCO 2015 Annual Meeting
May 27, 2015

Blaze Bioscience A ppoints Jan Öhrström, M.D., to Its Board of Directors
April 1, 2015

Blaze Bioscience Announces Poster Presentation at the American Academy of Dermatology 73rd Ann ual Meeting
March 18, 2015

Blaze Bioscience Announces NCI SB IR Phase II Funding for Clinical Trial of Tumor PaintTM BLZ-100 in Sarcoma
October 8, 2014

Blaze Bioscience Anno unc es Ini tiatio n of Phase 1 b Brain Cancer Program for Tumor Pa intTM BLZ-100
September 25, 2014

Blaze Bios cience An nounces Presentation at the 2014 Wedbush PacGrow Life Sciences Managem ent Access Conference
August 13, 2014

Blaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical Study of BLZ-100
December 19, 2013

Blaze Bioscience Raises $9 million in Series B Financing
December 3, 2013

Blaze Bioscience and Fred Hutchinson Cancer Research Center Enter into Collaboration and Option Agreement in Support of Optides Discovery Program
July 3, 2013

Blaze Bioscience Announces Two Poster Presentations at AACR-SNMMI Conference and Award of NCI SBIR Contract Advancing Tumor Paint™ Technology
February 27, 2013

Blaze Bioscience Announces Completion of Series A Financing - Brings Total Investment to $9.8 Million
February 22, 2013

Blaze Bioscience Raises $5.0 Million in Series A Financing
June 8, 2012

Blaze Bioscience Licenses Tumor Paint Technology from Fred Hutchinson Cancer Research Center
October 18, 2011